Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Exclusion Criteria

• •Recurrence or distant metastasis nasopharyngeal carcinoma.
• •Keratinizing squamous cell carcinoma (WHO type I).
• •Pregnant or breastfeeding women, who are in their childbearing years and have not used effective contraception.
• •Previous or concurrently with other malignancies, exclude cured skin basal cell carcinoma and cervical carcinoma in situ.
• •Patients with severely diminished functions of the heart, liver, lung, kidney and bone marrow;
• •Serious, unmanaged medical conditions and infections.
• •Those with other therapeutic contraindications.
• •Use of other investigational medications or clinical studies concurrently.
• •Refused or incapacity to sign the informed consent to participate in the study.
• •People having mental or personality disorders, disability, or limited civil capacity.
• •Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
• •HGB\>130g/L(male)，HGB \>120g/L(female).
• •Received transfusion therapy before.
• •Receipt of oral or IV iron supplements or ESAs up to 4 weeks before inclusion
• •Ferritin \> 800 ng/ml
• •Ongoing bleeding.